MiR-126 contributes to Parkinson's disease by dysregulating the insulin-like growth factor/phosphoinositide 3-kinase signaling

Neurobiology of Aging

Volumn 35, Issue 7, 2014, Pages 1712-1721

  Kim, Woori ^a,e   Lee, Yenarae ^a   McKenna, Noah D ^a   Yi, Ming ^b   Simunovic, Filip ^a   Wang, Yulei ^c   Kong, Benjamin ^c   Rooney, Robert J ^d   Seo, Hyemyung ^e   Stephens, Robert M ^b   Sonntag, Kai C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Life Technologies Corporation   (United States)

^d Genome Explorations Inc   (United States)

^e Hanyang University   (South Korea)

Author keywords

6 OHDA neurotoxicity; Cell systems; Dopamine neurons; IGF 1 signaling; Insulin; Laser capture microdissection; MiR 126; MiRNAs; Parkinson's disease; PI3K; Postmortem

Indexed keywords

DOPAMINE; INSULIN RECEPTOR SUBSTRATE 1; MICRORNA 126; OXIDOPAMINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P85; PROTEIN P85 BETA; SOMATOMEDIN C; SPROUTY PROTEIN; SPROUTY RELATED EVH1 DOMAIN CONTAINING PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; EMBRYO; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; NEUROPROTECTION; NEUROTOXICITY; NEUROTROPISM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RAT; RNA ANALYSIS; SIGNAL TRANSDUCTION;

6-OHDA NEUROTOXICITY; CELL SYSTEMS; DOPAMINE NEURONS; IGF-1 SIGNALING; INSULIN; LASER CAPTURE MICRODISSECTION; MIR-126; MIRNAS; PARKINSON'S DISEASE; PI3K; POSTMORTEM;

BRAIN; CELLS, CULTURED; DOPAMINERGIC NEURONS; DOWN-REGULATION; GENE EXPRESSION REGULATION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICRORNAS; OXIDOPAMINE; PARKINSON DISEASE; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 84903363869     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.01.021     Document Type: Article

References (60)

1. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
2. Benes F.M., Lim B., Matzilevich D., Walsh J.P., Subburaju S., Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc. Natl. Acad. Sci. U.S.A 2007, 104:10164-10169.
3. Bomfim T.R., Forny-Germano L., Sathler L.B., Brito-Moreira J., Houzel J.C., Decker H., Silverman M.A., Kazi H., Melo H.M., McClean P.L., Holscher C., Arnold S.E., Talbot K., Klein W.L., Munoz D.P., Ferreira S.T., De Felice F.G. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J.Clin. Invest. 2012, 122:1339-1353. 10.1172/JCI57256.
4. Braak H., Del Tredici K. Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 2008, 70:1916-1925.
5. Cantuti-Castelvetri I., Keller-McGandy C., Bouzou B., Asteris G., Clark T.W., Frosch M.P., Standaert D.G. Effects of gender on nigral gene expression and parkinson disease. Neurobiol. Dis. 2007, 26:606-614.
6. Chung C.Y., Seo H., Sonntag K.C., Brooks A., Lin L., Isacson O. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum. Mol. Genet. 2005, 14:1709-1725.
7. Chung J., Kubota H., Ozaki Y., Uda S., Kuroda S. Timing-dependent actions of NGF required for cell differentiation. PLoS One 2010, 5:e9011. 10.1371/journal.pone.0009011.
8. Craft S., Watson G.S. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004, 3:169-178.
9. Crawford M., Brawner E., Batte K., Yu L., Hunter M.G., Otterson G.A., Nuovo G., Marsh C.B., Nana-Sinkam S.P. MicroRNA-126 inhibits invasion in non-small cell lung carcinoma cell lines. Biochem. Biophys. Res. Commun. 2008, 373:607-612.
10. D'Haene B., Mestdagh P., Hellemans J., Vandesompele J. miRNA expression profiling: from reference genes to global mean normalization. Methods Mol. Biol. 2012, 822:261-272.
11. Das A.T., Zhou X., Vink M., Klaver B., Verhoef K., Marzio G., Berkhout B. Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J.Biol. Chem. 2004, 279:18776-18782.
12. de la Monte S.M. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 2012, 9:35-66.
13. Deak F., Sonntag W.E. Aging, synaptic dysfunction, and insulin-like growth factor (IGF)-1. J.Gerontol A Biol. Sci. Med. Sci. 2012, 67:611-625. 10.1093/gerona/gls118.
14. Deo A., Carlsson J., Lindlof A. How to choose a normalization strategy for miRNA quantitative real-time (qPCR) arrays. J.Bioinform. Comput. Biol. 2011, 9:795-812.
15. Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J.Biol. Chem. 2010, 285:12726-12734. 10.1074/jbc.M109.086827.
16. Du L., Pertsemlidis A. Cancer and neurodegenerative disorders: pathogenic convergence through microRNA regulation. J.Mol. Cell. Biol. 2011, 3:176-180.
17. Eacker S.M., Dawson T.M., Dawson V.L. Understanding microRNAs in neurodegeneration. Nat. Rev. Neurosci. 2009, 10:837-841.
18. Elstner M., Morris C.M., Heim K., Bender A., Mehta D., Jaros E., Klopstock T., Meitinger T., Turnbull D.M., Prokisch H. Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death. Acta Neuropathol. 2011, 122:75-86. 10.1007/s00401-011-0828-9.
19. Fish J.E., Santoro M.M., Morton S.U., Yu S., Yeh R.F., Wythe J.D., Ivey K.N., Bruneau B.G., Stainier D.Y., Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 2008, 15:272-284.
20. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19:92-105.
21. Grimson A., Farh K.K., Johnston W.K., Garrett-Engele P., Lim L.P., Bartel D.P. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 2007, 27:91-105.
22. Guo C., Sah J.F., Beard L., Willson J.K., Markowitz S.D., Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 2008, 47:939-946.
23. Heyer M.P., Pani A.K., Smeyne R.J., Kenny P.J., Feng G. Normal midbrain dopaminergic neuron development and function in miR-133b mutant mice. J.Neurosci. 2012, 32:10887-10894. 10.1523/JNEUROSCI.1732-12.2012.
24. Hu Y.K., Wang X., Li L., Du Y.H., Ye H.T., Li C.Y. MicroRNA-98 induces an Alzheimer's disease-like disturbance by targeting insulin-like growth factor 1. Neurosci. Bull. 2013, 10.1007/s12264-013-1348-5.
25. Junn E., Lee K.W., Jeong B.S., Chan T.W., Im J.Y., Mouradian M.M. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. U.S.A 2009, 106:13052-13057.
26. Kefas B., Godlewski J., Comeau L., Li Y., Abounader R., Hawkinson M., Lee J., Fine H., Chiocca E.A., Lawler S., Purow B. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008, 68:3566-3572. 10.1158/0008-5472.CAN-07-6639.
27. Kim B., Feldman E.L. Insulin resistance in the nervous system. Trends Endocrinol. Metab. 2012, 23:133-141. 10.1016/j.tem.2011.12.004.
28. Kim E.K., Choi E.J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta 2010, 1802:396-405. 10.1016/j.bbadis.2009.12.009.
29. Kim J., Inoue K., Ishii J., Vanti W.B., Voronov S.V., Murchison E., Hannon G., Abeliovich A. AmicroRNA feedback circuit in midbrain dopamine neurons. Science 2007, 317:1220-1224.
30. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
31. Liang R., Khanna A., Muthusamy S., Li N., Sarojini H., Kopchick J.J., Masternak M.M., Bartke A., Wang E. Post-transcriptional regulation of IGF1R by key microRNAs in long-lived mutant mice. Aging Cell 2011, 10:1080-1088. 10.1111/j.1474-9726.2011.00751.x.
32. Ling H.Y., Ou H.S., Feng S.D., Zhang X.Y., Tuo Q.H., Chen L.X., Zhu B.Y., Gao Z.P., Tang C.K., Yin W.D., Zhang L., Liao D.F. Changes in microRNA (miR) profile and effects of miR-320 in insulin-resistant 3T3-L1 adipocytes. Clin. Exp. Pharmacol. Physiol. 2009, 36:e32-e39. 10.1111/j.1440-1681.2009.05207.x.
33. Mestdagh P., Van Vlierberghe P., De Weer A., Muth D., Westermann F., Speleman F., Vandesompele J. Anovel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009, 10:R64. 10.1186/gb-2009-10-6-r64.
34. Minones-Moyano E., Porta S., Escaramis G., Rabionet R., Iraola S., Kagerbauer B., Espinosa-Parrilla Y., Ferrer I., Estivill X., Marti E. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum. Mol. Genet. 2011, 20:3067-3078. 10.1093/hmg/ddr210.
35. Nelson P.T., Wang W.X., Rajeev B.W. MicroRNAs (miRNAs) in neurodegenerative diseases. Brain Pathol. 2008, 18:130-138.
36. Oglesby I.K., Bray I.M., Chotirmall S.H., Stallings R.L., O'Neill S.J., McElvaney N.G., Greene C.M. miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. J.Immunol. 2010, 184:1702-1709.
37. Pietersen C.Y., Lim M.P., Macey L., Woo T.U., Sonntag K.C. Neuronal type-specific gene expression profiling and laser-capture microdissection. Methods Mol. Biol. 2011, 755:327-343.
38. Presgraves S.P., Ahmed T., Borwege S., Joyce J.N. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox. Res. 2004, 5:579-598.
39. Ryu H.S., Park S.Y., Ma D., Zhang J., Lee W. The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. PLoS One 2011, 6:e17343.
40. Sastry L., Johnson T., Hobson M.J., Smucker B., Cornetta K. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods. Gene Ther. 2002, 9:1155-1162. 10.1038/sj.gt.3301731.
41. Schapira A.H., Jenner P. Etiology and pathogenesis of Parkinson's disease. Move. Disord. 2011, 26:1049-1055. 10.1002/mds.23732.
42. Seo H., Sonntag K.C., Isacson O. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann. Neurol. 2004, 56:319-328.
43. Seo H., Sonntag K.C., Kim W., Cattaneo E., Isacson O. Proteasome activator enhances survival of Huntington's disease neuronal model cells. PLoS One 2007, 2:e238.
44. Sethupathy P., Megraw M., Hatzigeorgiou A.G. Aguide through present computational approaches for the identification of mammalian microRNA targets. Nat. Methods 2006, 3:881-886.
45. Simunovic F., Yi M., Wang Y., Macey L., Brown L.T., Krichevsky A.M., Andersen S.L., Stephens R.M., Benes F.M., Sonntag K.C. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 2009, 132(Pt 7):1795-1809.
46. Simunovic F., Yi M., Wang Y., Stephens R., Sonntag K.C. Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease. PLoS One 2010, 5:e8856.
47. Sonntag K.C. MicroRNAs and deregulated gene expression networks in neurodegeneration. Brain Res. 2010, 1338:48-57.
48. Sonntag K.C., Woo T.U., Krichevsky A.M. Converging miRNA functions in diverse brain disorders: a case for miR-124 and miR-126. Exp. Neurol. 2012, 235:427-435. 10.1016/j.expneurol.2011.11.035.
49. Talbot K., Wang H.Y., Kazi H., Han L.Y., Bakshi K.P., Stucky A., Fuino R.L., Kawaguchi K.R., Samoyedny A.J., Wilson R.S., Arvanitakis Z., Schneider J.A., Wolf B.A., Bennett D.A., Trojanowski J.Q., Arnold S.E. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J.Clin. Invest. 2012, 122:1316-1338. 10.1172/JCI59903.
50. Torres-Aleman I. Toward a comprehensive neurobiology of IGF-I. Dev. Neurobiol. 2010, 70:384-396.
51. Wang G., van der Walt J.M., Mayhew G., Li Y.J., Zuchner S., Scott W.K., Martin E.R., Vance J.M. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am. J. Hum. Genet. 2008, 82:283-289.
52. Wang S., Aurora A.B., Johnson B.A., Qi X., McAnally J., Hill J.A., Richardson J.A., Bassel-Duby R., Olson E.N. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 2008, 15:261-271.
53. Wang X.H., Qian R.Z., Zhang W., Chen S.F., Jin H.M., Hu R.M. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin. Exp. Pharmacol. Physiol. 2009, 36:181-188.
54. Wirdefeldt K., Adami H.O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 2011, 26(Suppl 1):S1-58. 10.1007/s10654-011-9581-6.
55. Xiao F., Zuo Z., Cai G., Kang S., Gao X., Li T. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res. 2009, 37(Database issue):D105-D110.
56. Yi M., Mudunuri U., Che A., Stephens R.M. Seeking unique and common biological themes in multiple gene lists or datasets: pathway pattern extraction pipeline for pathway-level comparative analysis. BMC Bioinformatics 2009, 10:200.
57. Zhang J., Du Y.Y., Lin Y.F., Chen Y.T., Yang L., Wang H.J., Ma D. The cell growth suppressor, mir-126, targets IRS-1. Biochem. Biophys. Res. Commun. 2008, 377:136-140.
58. Zhu N., Zhang D., Xie H., Zhou Z., Chen H., Hu T., Bai Y., Shen Y., Yuan W., Jing Q., Qin Y. Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol. Cell Biochem. 2011, 351:157-164.
59. Zufferey R., Nagy D., Mandel R.J., Naldini L., Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery invivo. Nat. Biotechnol. 1997, 15:871-875.
60. Zufferey R., Dull T., Mandel R.J., Bukovsky A., Quiroz D., Naldini L., Trono D. Self-inactivating lentivirus vector for safe and efficient invivo gene delivery. J.Virol. 1998, 72:9873-9880.